Review




Structured Review

Daiichi Sankyo txa
Txa, supplied by Daiichi Sankyo, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/txa/txa/pmc12897568-100-8-9
Average 86 stars, based on 1 article reviews
txa - by Bioz Stars, 2026-11
86/100 stars

Images

Related Articles

Saline:

Article Title: Efficacy of intravenous tranexamic acid administration in medial opening-wedge distal tibial tuberosity osteotomy (MOWDTO) for varus knee osteoarthritis: a randomized control trial.
Article Snippet: .. In the TXA group, patients received 1000 mg of TXA diluted by 100 ml of saline intravenously (Transamin; Daiichi Sankyo, Tokyo, Japan) before skin incision and 6 h after the first dose. ..

Injection:

Article Title: The Efficacy of Intra-articular Tranexamic Acid Injection With Different Drainage Clamping Time in Postoperative Bleeding and Pain After Arthroscopic Anterior Cruciate Ligament Reconstruction
Article Snippet: .. Additionally, in the TXA group, 10 mL of TXA solution (100 mg/mL; Daiichi Sankyo, Tokyo, Japan) was injected into the joint, and all closed suction drains were clamped for 4, or 8 hours based on the grouping results. ..

Article Title: Effects of intra-articular tranexamic acid injection with different acting times after anterior cruciate ligament reconstruction: a cohort study with historical controls.
Article Snippet: .. A total of 10 mL of TXA (100 mg/mL; Daiichi Sankyo, Tokyo, Japan) was then injected into the joint before the release of the tourniquet. ..

Article Title: Intra-articular Injection of Tranexamic Acid Reduced Postoperative Hemarthrosis in Arthroscopic Anterior Cruciate Ligament Reconstruction: A Prospective Randomized Study.
Article Snippet: Purpose: To evaluate the effect of intra-articular injection of tranexamic acid (TXA) in patients receiving arthroscopic anterior cruciate ligament reconstruction (ACLR).. Methods: A total of 304 patients were included in this study, which was performed between August 2017 and April 2018.. Single-bundle reconstructions using autologous hamstring tendon grafts were performed in all patients.

Control:

Article Title: Tranexamic Acid for Acute Upper Respiratory Tract Infection‐Associated Sore Throat Pain: A Randomized Controlled Trial
Article Snippet: .. They either received 1 g preparation of 50% TXA (Daiichi Sankyo Co., Chuo‐ku, Tokyo, Japan) in powder form (intervention) or 1 g lactose placebo in powder form (control). ..

Article Title: Antifibrinolytics for heavy menstrual bleeding
Article Snippet: Published by John Wiley & Sons, Ltd. Preston 1995 (Continued) Exclusion criteria: abnormal renal function; abnormal pelvic examination; abnormal cervical smear; anovulatory cycles; lack of compliance during the placebo cycles Interventions 2 months of placebo (to assess eligibility) followed by 2 months of either TXA (25 participants) 1 g taken 4 times daily on days 1 to 4 or NET (21 participants) 5 mg taken twice daily on days 19 to 26 of cycle Outcomes Objective MBL: measured via the alkaline haematin method (end scores) QoL assessed using a questionnaire (at end of cycle 2 and cycle 4) using 5-point scale for general health, amount of flooding and leakage experienced, abdominal pain, limitation to social life, effect on sex life Diary of days bleeding, number of sanitary towels used and side effects recorded by participants Notes Originally 103 women were recruited but 57 were excluded during the placebo cycles because of lack of objective menorrhagia (> 80 mL per cycle), anovulation or lack of compliance with protocol Additional data were provided by the author Funded by Pharmacia (a drug company) Risk of bias Bias Authors’ judgement Support for judgement Random sequence generation (selection bias) Low risk “Randomization was by computer generated numbers” Allocation concealment (selection bias) Low risk Adequate: “opaque sealed, consecutively numbered envelopes” Blinding (performance bias and detection bias) All outcomes Low risk Authors stated that the other group took “placebo of identical appearance to the active drug” and the treatment regimen was also the same for each group Incomplete outcome data (attrition bias) All outcomes Low risk 4 women did not complete the trial, but all were included in the results Selective reporting (reporting bias) Low risk All pre-specified outcomes were reported Other bias Low risk Groups appeared comparable at baseline 50Antifibrinolytics for heavy menstrual bleeding (Review) Copyright © 2018 The Cochrane Collaboration. .. Published by John Wiley & Sons, Ltd. Zhang 2008 Methods Multi-centre, open label RCT: method of randomization used computer software Blinding was highly unlikely, given the differences in the treatment regimens (1 group took tablets twice a day, the other 3 times a day) Given treatment for 2 cycles, then followed-up for 1 further cycle Participants Country: China Age: mean age 35 years old Number of participants: 106 women Inclusion criteria: “proven ovulatory menorrhagia”, attending gynaecological clinics, PBAC score > 130 Exclusion criteria: heart, kidney, liver or haematological disease; having had any hormonal treatments in the 3 months prior, including an IUS; previous thrombo-embolus Interventions TXA 1 g 3 times daily during days 1 to 5 (69 participants) versus NET 5 mg twice daily on days 19 to 26 (59 participants) Administered for 2 consecutive cycles Outcomes MBL (PBAC) Length of menstrual period 6-item QoL questionnaire collected in the second week before, during and after each treatment cycle and a third (follow-up) cycle Notes Funded by Daiichi Sankyo Co Ltd (a Japanese drug company) Risk of bias Bias Authors’ judgement Support for judgement Random sequence generation (selection bias) Low risk Used computer software to allocate participants randomly Allocation concealment (selection bias) Unclear risk Not reported Blinding (performance bias and detection bias) All outcomes High risk Treatment and control groups were given their pills on different days of the menstrual cycle Incomplete outcome data (attrition bias) All outcomes Low risk It appears that there is minimal drop-out Selective reporting (reporting bias) High risk The authors only report significant results in the abstract, which appears to favour the experimental treatment (TXA) For example, QoL scores were significantly improved after 1 cycle of treatment in the TXA group, but after 2 cycles of treatment and at follow-up the scores were similar These latter findings were not reported, which suggests that the conclusions are in- 51Antifibrinolytics for heavy menstrual bleeding (Review) Copyright © 2018 The Cochrane Collaboration. ..

Software:

Article Title: Antifibrinolytics for heavy menstrual bleeding
Article Snippet: Published by John Wiley & Sons, Ltd. Preston 1995 (Continued) Exclusion criteria: abnormal renal function; abnormal pelvic examination; abnormal cervical smear; anovulatory cycles; lack of compliance during the placebo cycles Interventions 2 months of placebo (to assess eligibility) followed by 2 months of either TXA (25 participants) 1 g taken 4 times daily on days 1 to 4 or NET (21 participants) 5 mg taken twice daily on days 19 to 26 of cycle Outcomes Objective MBL: measured via the alkaline haematin method (end scores) QoL assessed using a questionnaire (at end of cycle 2 and cycle 4) using 5-point scale for general health, amount of flooding and leakage experienced, abdominal pain, limitation to social life, effect on sex life Diary of days bleeding, number of sanitary towels used and side effects recorded by participants Notes Originally 103 women were recruited but 57 were excluded during the placebo cycles because of lack of objective menorrhagia (> 80 mL per cycle), anovulation or lack of compliance with protocol Additional data were provided by the author Funded by Pharmacia (a drug company) Risk of bias Bias Authors’ judgement Support for judgement Random sequence generation (selection bias) Low risk “Randomization was by computer generated numbers” Allocation concealment (selection bias) Low risk Adequate: “opaque sealed, consecutively numbered envelopes” Blinding (performance bias and detection bias) All outcomes Low risk Authors stated that the other group took “placebo of identical appearance to the active drug” and the treatment regimen was also the same for each group Incomplete outcome data (attrition bias) All outcomes Low risk 4 women did not complete the trial, but all were included in the results Selective reporting (reporting bias) Low risk All pre-specified outcomes were reported Other bias Low risk Groups appeared comparable at baseline 50Antifibrinolytics for heavy menstrual bleeding (Review) Copyright © 2018 The Cochrane Collaboration. .. Published by John Wiley & Sons, Ltd. Zhang 2008 Methods Multi-centre, open label RCT: method of randomization used computer software Blinding was highly unlikely, given the differences in the treatment regimens (1 group took tablets twice a day, the other 3 times a day) Given treatment for 2 cycles, then followed-up for 1 further cycle Participants Country: China Age: mean age 35 years old Number of participants: 106 women Inclusion criteria: “proven ovulatory menorrhagia”, attending gynaecological clinics, PBAC score > 130 Exclusion criteria: heart, kidney, liver or haematological disease; having had any hormonal treatments in the 3 months prior, including an IUS; previous thrombo-embolus Interventions TXA 1 g 3 times daily during days 1 to 5 (69 participants) versus NET 5 mg twice daily on days 19 to 26 (59 participants) Administered for 2 consecutive cycles Outcomes MBL (PBAC) Length of menstrual period 6-item QoL questionnaire collected in the second week before, during and after each treatment cycle and a third (follow-up) cycle Notes Funded by Daiichi Sankyo Co Ltd (a Japanese drug company) Risk of bias Bias Authors’ judgement Support for judgement Random sequence generation (selection bias) Low risk Used computer software to allocate participants randomly Allocation concealment (selection bias) Unclear risk Not reported Blinding (performance bias and detection bias) All outcomes High risk Treatment and control groups were given their pills on different days of the menstrual cycle Incomplete outcome data (attrition bias) All outcomes Low risk It appears that there is minimal drop-out Selective reporting (reporting bias) High risk The authors only report significant results in the abstract, which appears to favour the experimental treatment (TXA) For example, QoL scores were significantly improved after 1 cycle of treatment in the TXA group, but after 2 cycles of treatment and at follow-up the scores were similar These latter findings were not reported, which suggests that the conclusions are in- 51Antifibrinolytics for heavy menstrual bleeding (Review) Copyright © 2018 The Cochrane Collaboration. ..

Sequencing:

Article Title: Antifibrinolytics for heavy menstrual bleeding
Article Snippet: Published by John Wiley & Sons, Ltd. Preston 1995 (Continued) Exclusion criteria: abnormal renal function; abnormal pelvic examination; abnormal cervical smear; anovulatory cycles; lack of compliance during the placebo cycles Interventions 2 months of placebo (to assess eligibility) followed by 2 months of either TXA (25 participants) 1 g taken 4 times daily on days 1 to 4 or NET (21 participants) 5 mg taken twice daily on days 19 to 26 of cycle Outcomes Objective MBL: measured via the alkaline haematin method (end scores) QoL assessed using a questionnaire (at end of cycle 2 and cycle 4) using 5-point scale for general health, amount of flooding and leakage experienced, abdominal pain, limitation to social life, effect on sex life Diary of days bleeding, number of sanitary towels used and side effects recorded by participants Notes Originally 103 women were recruited but 57 were excluded during the placebo cycles because of lack of objective menorrhagia (> 80 mL per cycle), anovulation or lack of compliance with protocol Additional data were provided by the author Funded by Pharmacia (a drug company) Risk of bias Bias Authors’ judgement Support for judgement Random sequence generation (selection bias) Low risk “Randomization was by computer generated numbers” Allocation concealment (selection bias) Low risk Adequate: “opaque sealed, consecutively numbered envelopes” Blinding (performance bias and detection bias) All outcomes Low risk Authors stated that the other group took “placebo of identical appearance to the active drug” and the treatment regimen was also the same for each group Incomplete outcome data (attrition bias) All outcomes Low risk 4 women did not complete the trial, but all were included in the results Selective reporting (reporting bias) Low risk All pre-specified outcomes were reported Other bias Low risk Groups appeared comparable at baseline 50Antifibrinolytics for heavy menstrual bleeding (Review) Copyright © 2018 The Cochrane Collaboration. .. Published by John Wiley & Sons, Ltd. Zhang 2008 Methods Multi-centre, open label RCT: method of randomization used computer software Blinding was highly unlikely, given the differences in the treatment regimens (1 group took tablets twice a day, the other 3 times a day) Given treatment for 2 cycles, then followed-up for 1 further cycle Participants Country: China Age: mean age 35 years old Number of participants: 106 women Inclusion criteria: “proven ovulatory menorrhagia”, attending gynaecological clinics, PBAC score > 130 Exclusion criteria: heart, kidney, liver or haematological disease; having had any hormonal treatments in the 3 months prior, including an IUS; previous thrombo-embolus Interventions TXA 1 g 3 times daily during days 1 to 5 (69 participants) versus NET 5 mg twice daily on days 19 to 26 (59 participants) Administered for 2 consecutive cycles Outcomes MBL (PBAC) Length of menstrual period 6-item QoL questionnaire collected in the second week before, during and after each treatment cycle and a third (follow-up) cycle Notes Funded by Daiichi Sankyo Co Ltd (a Japanese drug company) Risk of bias Bias Authors’ judgement Support for judgement Random sequence generation (selection bias) Low risk Used computer software to allocate participants randomly Allocation concealment (selection bias) Unclear risk Not reported Blinding (performance bias and detection bias) All outcomes High risk Treatment and control groups were given their pills on different days of the menstrual cycle Incomplete outcome data (attrition bias) All outcomes Low risk It appears that there is minimal drop-out Selective reporting (reporting bias) High risk The authors only report significant results in the abstract, which appears to favour the experimental treatment (TXA) For example, QoL scores were significantly improved after 1 cycle of treatment in the TXA group, but after 2 cycles of treatment and at follow-up the scores were similar These latter findings were not reported, which suggests that the conclusions are in- 51Antifibrinolytics for heavy menstrual bleeding (Review) Copyright © 2018 The Cochrane Collaboration. ..

Selection:

Article Title: Antifibrinolytics for heavy menstrual bleeding
Article Snippet: Published by John Wiley & Sons, Ltd. Preston 1995 (Continued) Exclusion criteria: abnormal renal function; abnormal pelvic examination; abnormal cervical smear; anovulatory cycles; lack of compliance during the placebo cycles Interventions 2 months of placebo (to assess eligibility) followed by 2 months of either TXA (25 participants) 1 g taken 4 times daily on days 1 to 4 or NET (21 participants) 5 mg taken twice daily on days 19 to 26 of cycle Outcomes Objective MBL: measured via the alkaline haematin method (end scores) QoL assessed using a questionnaire (at end of cycle 2 and cycle 4) using 5-point scale for general health, amount of flooding and leakage experienced, abdominal pain, limitation to social life, effect on sex life Diary of days bleeding, number of sanitary towels used and side effects recorded by participants Notes Originally 103 women were recruited but 57 were excluded during the placebo cycles because of lack of objective menorrhagia (> 80 mL per cycle), anovulation or lack of compliance with protocol Additional data were provided by the author Funded by Pharmacia (a drug company) Risk of bias Bias Authors’ judgement Support for judgement Random sequence generation (selection bias) Low risk “Randomization was by computer generated numbers” Allocation concealment (selection bias) Low risk Adequate: “opaque sealed, consecutively numbered envelopes” Blinding (performance bias and detection bias) All outcomes Low risk Authors stated that the other group took “placebo of identical appearance to the active drug” and the treatment regimen was also the same for each group Incomplete outcome data (attrition bias) All outcomes Low risk 4 women did not complete the trial, but all were included in the results Selective reporting (reporting bias) Low risk All pre-specified outcomes were reported Other bias Low risk Groups appeared comparable at baseline 50Antifibrinolytics for heavy menstrual bleeding (Review) Copyright © 2018 The Cochrane Collaboration. .. Published by John Wiley & Sons, Ltd. Zhang 2008 Methods Multi-centre, open label RCT: method of randomization used computer software Blinding was highly unlikely, given the differences in the treatment regimens (1 group took tablets twice a day, the other 3 times a day) Given treatment for 2 cycles, then followed-up for 1 further cycle Participants Country: China Age: mean age 35 years old Number of participants: 106 women Inclusion criteria: “proven ovulatory menorrhagia”, attending gynaecological clinics, PBAC score > 130 Exclusion criteria: heart, kidney, liver or haematological disease; having had any hormonal treatments in the 3 months prior, including an IUS; previous thrombo-embolus Interventions TXA 1 g 3 times daily during days 1 to 5 (69 participants) versus NET 5 mg twice daily on days 19 to 26 (59 participants) Administered for 2 consecutive cycles Outcomes MBL (PBAC) Length of menstrual period 6-item QoL questionnaire collected in the second week before, during and after each treatment cycle and a third (follow-up) cycle Notes Funded by Daiichi Sankyo Co Ltd (a Japanese drug company) Risk of bias Bias Authors’ judgement Support for judgement Random sequence generation (selection bias) Low risk Used computer software to allocate participants randomly Allocation concealment (selection bias) Unclear risk Not reported Blinding (performance bias and detection bias) All outcomes High risk Treatment and control groups were given their pills on different days of the menstrual cycle Incomplete outcome data (attrition bias) All outcomes Low risk It appears that there is minimal drop-out Selective reporting (reporting bias) High risk The authors only report significant results in the abstract, which appears to favour the experimental treatment (TXA) For example, QoL scores were significantly improved after 1 cycle of treatment in the TXA group, but after 2 cycles of treatment and at follow-up the scores were similar These latter findings were not reported, which suggests that the conclusions are in- 51Antifibrinolytics for heavy menstrual bleeding (Review) Copyright © 2018 The Cochrane Collaboration. ..



Similar Products

86
Pfizer Inc tranexamic acid txa treatment 136 txa
Tranexamic Acid Txa Treatment 136 Txa, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/txa/acid+tranexamic/pm42314039-83-2-9
Average 86 stars, based on 1 article reviews
tranexamic acid txa treatment 136 txa - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Jhpiego Corporation txa
Txa, supplied by Jhpiego Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/txa/txa/pm42260007-138-26-12
Average 86 stars, based on 1 article reviews
txa - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Wolters Kluwer Health gastroenterology tranexamic acid txa
Gastroenterology Tranexamic Acid Txa, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/txa/acid+tranexamic/pm41860133-47-13-2
Average 86 stars, based on 1 article reviews
gastroenterology tranexamic acid txa - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Daihan Scientific tranexamic acid txa
Tranexamic Acid Txa, supplied by Daihan Scientific, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/txa/acid+tranexamic+txa/us12558405-192-0-6
Average 86 stars, based on 1 article reviews
tranexamic acid txa - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Daiichi Sankyo txa
Txa, supplied by Daiichi Sankyo, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/txa/txa/pmc12897568-100-8-9
Average 86 stars, based on 1 article reviews
txa - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

94
ATCC txa 709
Txa 709, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/txa/c8182/pmc12802965-74-12-23
Average 94 stars, based on 1 article reviews
txa 709 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

86
Wolters Kluwer Health txa
Txa, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/txa/txa/10__1097_slash_sap__0000000000004586-73-9-3
Average 86 stars, based on 1 article reviews
txa - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Pfizer Inc iv txa
Average PBAC score of lochial blood loss reported by participant diary over 21 days. One participant in <t>the</t> <t>rVWF</t> <t>+TXA</t> group did not complete a diary.
Iv Txa, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/txa/acid+tranexamic/pmc12686688-100-9-12
Average 86 stars, based on 1 article reviews
iv txa - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Macklin Inc txa
Average PBAC score of lochial blood loss reported by participant diary over 21 days. One participant in <t>the</t> <t>rVWF</t> <t>+TXA</t> group did not complete a diary.
Txa, supplied by Macklin Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/txa/txa/pm41192092-35-6-12
Average 86 stars, based on 1 article reviews
txa - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Shanxin Zhenxing Group Co Ltd txa
Average PBAC score of lochial blood loss reported by participant diary over 21 days. One participant in <t>the</t> <t>rVWF</t> <t>+TXA</t> group did not complete a diary.
Txa, supplied by Shanxin Zhenxing Group Co Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/txa/based+txa/10__1007_slash_s11664___025___12488___0-17-14-78
Average 86 stars, based on 1 article reviews
txa - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

Image Search Results


Average PBAC score of lochial blood loss reported by participant diary over 21 days. One participant in the rVWF +TXA group did not complete a diary.

Journal: Blood Advances

Article Title: Impact of tranexamic acid on postpartum hemorrhage in type 1 von Willebrand disease treated with recombinant VWF

doi: 10.1182/bloodadvances.2025017046

Figure Lengend Snippet: Average PBAC score of lochial blood loss reported by participant diary over 21 days. One participant in the rVWF +TXA group did not complete a diary.

Article Snippet: Participants randomized to the rVWF + TXA group received IV TXA (Cyclokapron, Pfizer Pharmaceuticals, San Diego, CA), 1 g (100 mg/mL) infused over 10 minutes at a rate of 1 mL/min, administered within 3 hours of delivery.

Techniques: